Clinical trial NCT05658003: A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
Official title: An Open-label, Multi-center, Randomized, Phase II Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Keywords: Chinese adult male population
therapeutic agent lutetium (177Lu) vipivotide tetraxetan
[177Lu]Lu-PSMA-617
Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
rPFS
Prostate-specific Membrane Antigen
PSMA
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2022-12-20
Enrollment: 62
Sex: MALE
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy of \[177Lu\]Lu-PSMA-617 over a change of androgen receptor-directed therapy (ARDT) treatment in prolonging radiographic progression free survival (rPFS) in Chinese metastatic castration-resistant prostate cancer patients, who were previously treated with another ARDT as last treatment and who have not been exposed to a taxane-containing regimen in castrate resistant prostate cancer (CRPC) or hormone-sensitive prostate cancer (HSPC) settings and who are considered appropriate for delaying taxane-based chemotherapy. The primary endpoint of rPFS will be assessed via blinded independent centralized review of radiographic images provided by the treating physician and as outlined in Prostate Cancer Working Group 3 (PCWG3) guidelines.

Detailed description: The study contains a screening period to assess the eligibility of participants, only participants fulfilling the \[68Ga\]Ga-PSMA-11 PET scan interpretation criteria for eligibility and meeting all other inclusion/exclusion criteria will be enrolled. In the randomization period, approximately 60 participants will be randomized 1:1 to receive \[177Lu\]Lu-PSMA-617 treatment or a change of approved ARDT treatment. Randomization will be stratified by symptomatology i.e., Asymptomatic or mildly symptomatic vs. symptomatic.

Participants randomized to \[177Lu\]Lu-PSMA-617 treatment group will receive 7.4 GBq (200 mCi) ± 10% \[177Lu\]Lu-PSMA-617 once every 6 weeks (± 1 week) for 6 cycles. For participants randomized to the ARDT treatment arm, the change of ARDT treatment for each participant will be selected by the treating physician prior to randomization and will be administered per the physician's orders. Supportive care will be allowed in both arms at the discretion of the investigator. ARDT must not be administrated concomitantly with \[177Lu\]Lu-PSMA-617.

Efficacy assessment will be performed every 8 weeks after first dose of study treatment for the first 24 weeks (week 9, 17, 25) and then every 12 weeks (week 37, 49, etc) until confirmation of radiographic progression by BICR. Upon confirmation of rPFS by BIRC, participants randomized to ARDT arm will be allowed to crossover to \[177Lu\]Lu-PSMA-617 treatment if the crossover criteria are met. Post-treatment follow up period will have a 30-day safety follow up post EOT visit and long term survival follow up.

Eligibility criteria: Key Inclusion criteria

1. Participants must be Chinese adult men \>= 18 years of age
2. Participants must have an ECOG performance status of 0 to 1
3. Participant must have histological pathological and/or cytological confirmation of adenocarcinoma of the prostate
4. Participants must be \[68Ga\]Ga-PSMA-11 PET/CT scan positive, and eligible as determined by the sponsor's central reader
5. Participants must have a castrate level of serum/plasma testosterone (\< 50 ng/dl, or \< 1.7 nmol/L)
6. Participants must have progressed only once on prior second generation ARDT (abiraterone, enzalutamide, darolutamide, or apalutamide)) in either HSPC or CRPC setting.

   * first generation androgen receptor inhibitor therapy (e.g. bicalutamide) is allowed but not considered as prior ARDT therapy
   * second generation ARDT must be the most recent therapy received
7. candidates for change in ARDT (eligible to receive abiraterone or enzalutamide) as assessed by the treating physician

   • Participants cannot have previously progressed nor had intolerable toxicity to both enzalutamide and abiraterone
8. Documented progressive mCRPC, based on at least 1 of the following criteria:

   * Serum/plasma PSA progression defined as 2 consecutive increases in PSA measured at least 1 week apart. the minimal start value is 2.0 ng/ml;
   * Soft-tissue progression defined based on PCWG3-modified RECIST v1.1(Eisenhauer et al 2009, Scher et al 2016)
   * Progression of bone disease: two new lesions; only positivity on the bone scan defines metastatic disease to bone (PCWG3 criteria Scher et al 2016)
9. Participants must have at least one metastatic lesion that is present on screening/baseline CT, MRI, or bone scan imaging obtained =\< 28 days prior to randomization
10. Participants must have adequate organ function:

    * Bone marrow reserve:
    * ANC \>= 1.5 x 109/L
    * Platelets \>= 100 x 109/L
    * Hemoglobin \>= 9 g/dL
    * Hepatic:
    * Total bilirubin \< 2 x the institutional upper limit of normal (ULN). For participants with known Gilbert's Syndrome =\< 3 x ULN is permitted
    * ALT or AST =\< 3.0 x ULN OR =\< 5.0 x ULN for participants with liver metastases
    * Albumin \>= 2.5 g/dL
    * Renal:
    * eGFR \>= 50 mL/min/1.73m2 using the Modification of Diet in Renal Disease (MDRD) equation

Key Exclusion criteria

1. Previous treatment with any of the following within 6 months of randomization: Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, Lutitium-177, Actium-225, hemi-body irradiation
2. Previous PSMA-targeted radioligand therapy
3. Prior treatment with PARP inhibitor, cytotoxic chemotherapy for castration resistant or castration sensitive prostate cancer (i.e., taxanes, platinum, estramustine, vincristine, methotrexate, etc.), immunotherapy or biological therapy (including monoclonal antibodies). \[Note: a maximum of 6 cycles of taxane exposure in the adjuvant or neo-adjuvant setting is allowed if 12 months have elapsed since completion of this adjuvant or neo-adjuvant therapy prior to randomization\]
4. Concurrent cytotoxic chemotherapy, immunotherapy, radioligand therapy, PARP inhibitor, biological, or investigational therapy
5. Transfusion or use of bone marrow stimulating agents for the sole purpose of making a participant eligible for study inclusion
6. Participants with a history of CNS metastases who are neurologically unstable, symptomatic, or receiving corticosteroids for the purpose of maintaining neurologic integrity.

   * Participants with CNS metastases are eligible if received therapy (surgery, radiotherapy, gamma knife), asymptomatic and neurologically stable without corticosteroids.
   * Participants with epidural disease, canal disease and prior cord involvement are eligible if those areas have been treated, are stable, and not neurologically impaired.
7. Symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression
8. Cardiac or cardiac repolarization abnormality, including any of the following:

   * History of myocardial infarction (MI), angina pectoris, or coronary artery bypass graft (CABG) within 6 months prior to starting study treatment
   * Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g., bifascicular block, Mobitz type II and third degree AV block) and QTc\>=500.
9. Concurrent serious (as determined by the Principal Investigator) medical conditions, including, but not limited to New York Heart Association class III or IV congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled infection, known active hepatitis B or C or other significant co-morbid conditions that in the opinion of the investigator would impair study participation or cooperation
10. Unmanageable concurrent bladder outflow obstruction or urinary incontinence. Note: Participants with bladder outflow obstruction or urinary incontinence, which is manageable and controlled with best available standard of care (incl. pads, drainage) are allowed.

Primary outcomes:
measure: Radiographic progression free survival (rPFS)
timeFrame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 42 months
Secondary outcomes:
measure: Overall survival (OS)
timeFrame: From date of randomization until date of death from any cause, assessed up to 59 months (estimated final OS analysis)
measure: Progression Free Survival (PFS)
timeFrame: From date of randomization until date of progression or date of death from any cause, whichever comes first, assessed up to 59 months (estimated final OS analysis)
measure: Prostate-specific antigen 50 response rate
timeFrame: Week 12, Week 24, Week 48
measure: Time to a first symptomatic skeletal event (TTSSE)
timeFrame: From date of randomization till date of death from any cause, whichever happens first, assessed up to 59 months (estimated final OS analysis)
measure: Time to Prostate Specific Antigen (PSA) progression
timeFrame: From date of randomization till date of Prostate Specific Antigen (PSA) progression, assessed up to 59 months (estimated OS analysis)
measure: Time to chemotherapy (TTCT)
timeFrame: From date of randomization until date of subsequent chemotherapy or date of death from any cause, whichever comes first, assessed up to 59 months (estimated final OS analysis)
measure: Overall response rate (ORR)
timeFrame: From date of randomization till 30 day safety follow-up or end of long term FU for patients prematurely discontinued, assessed up to 59 months (estimated final OS analysis)
measure: Disease control rate (DCR)
timeFrame: From date of randomization till 30 day safety follow-up or end of long term FU for patients prematurely discontinued, assessed up to 59 months (estimated final OS analysis)
measure: Time to response (TTR)
timeFrame: From date of randomization till 30 day safety follow-up or end of long term FU for patients prematurely discontinued, assessed up to 59 months (estimated final OS analysis)
measure: Duration of response (DOR)
timeFrame: From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 59 months (estimated final OS analysis)
measure: Time to soft tissue progression (TTSTP)
timeFrame: From date of randomization until date of soft tissue radiographic progression or date of death from any cause, whichever comes first, assessed up to 59 months (estimated final OS analysis)
measure: European Quality of Life (EuroQol) - 5 Domain 5 Level scale (EQ-5D- 5L)
timeFrame: From randomization up till 30 day safety follow-up or at LTFU2 (168 days after EOT) and LTFU4 (336 days after EOT) of long term FU for patients prematurely discontinued, assessed up to 59 Months (estimated final OS analysis)
measure: Functional Assessment of Cancer Therapy - Prostate (FACT-P) Questionnaire
timeFrame: From randomization up till 30 day safety follow-up or at LTFU2 (168 days after EOT) and LTFU4 (336 days after EOT) of long term FU for patients prematurely discontinued, assessed up to 59 Months (estimated final OS analysis)
measure: Brief Pain Inventory - Short Form (BPI-SF) Questionnaire
timeFrame: From randomization up till 30 day safety follow-up or at LTFU2 (168 days after EOT) and LTFU4 (336 days after EOT) of long term FU for patients prematurely discontinued, assessed up to 59 Months (estimated final OS analysis)
measure: Number of Participants with Treatment Emergent Adverse Events
timeFrame: From date of randomization till 30 days safety fup, assessed up to 59 months (estimated final OS analysis)
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Novartis Investigative Site
state: Hubei
city: Nanjing
country: China
facility: Novartis Investigative Site
state: Jiangsu
city: Nanjing
country: China
facility: Novartis Investigative Site
state: Jiangsu
city: Shenyang
country: China
facility: Novartis Investigative Site
state: Liaoning
city: Shanghai
country: China
facility: Novartis Investigative Site
state: Shanghai
city: Xian
country: China
facility: Novartis Investigative Site
state: Shanxi
city: Xian
country: China
facility: Novartis Investigative Site
state: Shanxi
city: Chengdu
country: China
facility: Novartis Investigative Site
state: Sichuan
city: Hangzhou
country: China
facility: Novartis Investigative Site
state: Zhejiang
city: Beijing
country: China
facility: Novartis Investigative Site
city: Beijing
country: China
facility: Novartis Investigative Site
city: Beijing
country: China
facility: Novartis Investigative Site
city: Guangzhou
country: China
facility: Novartis Investigative Site
city: Shanghai
country: China
facility: Novartis Investigative Site
city: Shanghai
country: China
facility: Novartis Investigative Site
city: Tianjin
country: China
facility: Novartis Investigative Site
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References: